MindMed’s MNMD Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed. “We have seen a meaningful acceleration in ...
Patients in the MM-120 clinical trial open the door to a nondescript Lauderhill medical facility off Oakland Park Boulevard and find themselves staring at a large seed-of-life symbol on the wall, ...
Source: By IndependentOo, Dominik from Germany, Maximilian IV, Laitche, NASA; composite artwork by Belbury - CC BY 4.0, Wikimedia Working in his lab at the pharmaceutical company Sandoz in 1938, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results